JAZZ vs TRS · P/E 1988, rev $2.28B vs P/E 122, rev $342.9M
Jazz Pharmaceuticals PLC (JAZZ) versus TriMas Corporation (TRS) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
TriMas Corporation (TRS) is a packaging & containers company listed on NASDAQ.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported TRS revenue for 2026-06-30 was $342.9M. Net income was $814.2M. TRS currently screens at market cap $1.53B and trailing P/E 121.8.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. TRS currently screens at market cap $1.53B and trailing P/E 121.8.
Not investment advice. Open the JAZZ and TRS stock pages for the full models.
Not investment advice.